“Given the high frequency and broad spectrum of germline gene sequence variations, these data suggest that genetic evaluation might be warranted for all patients diagnosed with this rare malignant tumor,” the researchers wrote. “A systemic sequencing effort for all patients with AC [appendix cancer] may also identify cancer vulnerabilities to exploit for therapeutic development in a cancer type for which clinical trials are limited.”